Muscular Dystrophy clinical trials
16 active trials name this condition. Describe your situation to see which ones you may be eligible for.
By location
- Nomad P-KAFO Study
- Toward Ubiquitous Lower Limb Exoskeleton Use in Children and Young Adults
- Genetics of Cardiovascular and Neuromuscular Disease
- Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
- Muscle Health Measurements Using Electrical Impedance Myography
- Investigational Use of Neuromuscular Ultrasound
- Congenital Muscle Disease Study of Patient and Family Reported Medical Information
- Study of Inherited Neurological Disorders
- Evaluating Long-term Use of a Pediatric Robotic Exoskeleton (P.REX/Agilik) to Improve Gait in Children With Movement Disorders
- Interfacing With NeuroTechnology to Expand Neural Throughput (INTENT)
- BrainGate2: Feasibility Study of an Intracortical Neural Interface System for Persons With Tetraplegia
- Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Speech-02)
- Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia
- Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Tablet-01)
- ECoG BMI for Motor and Speech Control
- iBCI Optimization for Veterans With Paralysis
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Muscular Dystrophy” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.